Press Releases April 8, 2025: MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033…MaaT PharmaApril 8, 2025
Press Releases February 29, 2024: MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS) MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial…MaaT PharmaFebruary 29, 2024
